

BGF backed Oxford Brain Diagnostics to roll out revolutionary technology for early diagnosis of dementia following regulatory approvals

19th May 2025, Oxford, UK: With over 55 million people currently living with dementia globally - a number expected to nearly double every 20 years - Oxford Brain Diagnostics' patented Cortical Disarray Measurement (CDM[®]) technology offers a breakthrough solution. The software provides an objective, quantifiable measure of neurodegeneration by analysing standard MRI scans, enabling timely and accurate assessment of brain health.

Following FDA 510(k) clearance and UKCA self-certification, OBD will now commence the commercial roll-out of its breakthrough technology to the USA and UK healthcare sectors. The technology has the potential to advance neurodegeneration diagnostics on a global scale.

Founded in 2019 by Dr Steven Chance (former Associate Professor of Neuroscience at Oxford University) and Professor Mark Jenkinson (Professor of Neuroimaging), OBD has built its technology on decades of expertise in brain pathology and imaging. The FDA recognised CDM's potential in 2020 by granting Breakthrough Device Designation status for evaluating adults at risk of Alzheimer's Disease.

In 2023 OBD secured a multi-million investment in a funding round led by BGF, the UK and Ireland's most active growth capital investor, alongside continued support from its existing investors, including the Oxford Technology & Innovations Fund (OTIF). This crucial investment enabled OBD to achieve both FDA 510(k) clearance and UKCA self-certification, enabling the company to secure clinical rollout and establishing the regulatory foundation for global market expansion.

Dr Steven Chance, CEO & Co-Founder of OBD, commented: "Neurodegenerative diseases represent a growing public health challenge, impacting millions of patients and their families worldwide. The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health."

Maggy Lau, Investor at BGF, added: "OBD's progress over the past two years has been remarkable. The technology is truly differentiated, and its recent regulatory achievements signal just how close it is to making a major impact. We're proud to back a business that's taking on one of the toughest and most important challenges in healthcare today."

The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer's drugs sharpening the focus on early, accurate diagnosis. OBD's technology directly

addresses this by enabling timely detection and precise monitoring of neurodegenerative disease. The company has already achieved early traction working with pharmaceutical partners to support clinical trials and drug development, while simultaneously expanding into healthcare settings.

Beyond dementia, OBD's platform shows promise in addressing other neurodegenerative conditions, including Parkinson's Disease and Multiple Sclerosis, expanding its potential impact across clinical and research domains.

About Oxford Brain Diagnostics Ltd

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's Cortical Disarray Measurement (CDM[®]) technology uses MRI brain scan data to create products to support early and differential diagnosis, track progression, and predict the decline due to neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

See: www.oxfordbraindiagnosics.com

About BGF

BGF was set up in 2011 and has invested £4.5 billion in over 600 companies, making it the most active investor in the UK. BGF is a minority, non-controlling equity partner with a patient outlook on investments, based on shared long-term goals with the management teams it backs. BGF invests in growing businesses in the UK and Ireland through its network of 15 offices.

See: www.bgf.co.uk